PALIPERIDONE (paliperidone) by Fosun Pharma is risperidone. Approved for schizophrenia [see )], schizoaffective disorder, an adjunct to mood stabilizers and/or antidepressant therapy [see )] and 2 more indications. First approved in 2018.
Drug data last refreshed 20h ago
risperidone. The mechanism of action of paliperidone in schizophrenia is unclear. However, the drug's therapeutic effect in schizophrenia could be mediated through a combination of central dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2A ) receptor antagonism.
Atypical Antipsychotic
Worked on PALIPERIDONE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
A Study of Paliperidone Palmitate 6-Month Formulation
A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities